Skip to content
Biodatica
Start free

Luminary Therapeutics, Inc.

Minneapolis, MN · also filed as None

Oncologygene editingFormed
Compare Sign in to watch

What changed

NIH S10 · $1.6M · Orbitrap Astral MS Instrument

5w agoNew grantJun 9, 2026Source filing (opens the source filing in a new tab)

Momentum

71no change

Momentum 71 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

~0months

The model puts this company near the end of its last raise.

Stage

Formed

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

15 pre-ticker oncology companies at Formed

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    S10 · $1.6M · non-dilutive

    Jun 15, 2026

    CASE WESTERN RESERVE UNIVERSITY · PI CHANCE, MARK R · OD · award ends Jun 14, 2027 · Orbitrap Astral MS Instrument

    NIH RePORTER · NIH RePORTER 11333540 (opens the source filing in a new tab)

  2. Filing

    Form D · $1.4M

    Nov 5, 2025

    Luminary Therapeutics, Inc. · private raise, self-reported by the issuer

    SEC EDGAR · 0001437749-25-033325 (opens the source filing in a new tab)

  3. Grant

    R56 · $380k · non-dilutive

    Sep 11, 2025

    UNIVERSITY OF MINNESOTA · PI REINEKE, THERESA M · NIAID · award ends Aug 31, 2026 · Bespoke Micellar Nanoparticles (MNPs) for In Vivo Delivery of Digital Base Editor Treatments for Primary Immunodeficiency Disease

    NIH RePORTER · NIH RePORTER 11359407 (opens the source filing in a new tab)

  4. Grant

    P50 · $227k · non-dilutive

    Jul 1, 2009

    MAYO CLINIC ROCHESTER · PI MORIARITY, BRANDEN S · NCI · award ends Aug 31, 2026 · Project 4 Treatment of Advanced Ovarian Cancer Using Gene-Edited NK CAR Cells

    NIH RePORTER · NIH RePORTER 11178546 (opens the source filing in a new tab)

  5. Grant

    P30 · $97k · non-dilutive

    Jun 1, 1998

    UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S · NCI · award ends Jan 31, 2029 · Genome Engineering Shared Resource

    NIH RePORTER · NIH RePORTER 11317272 (opens the source filing in a new tab)

  6. Grant

    P30 · $134k · non-dilutive

    Aug 1, 1997

    CASE WESTERN RESERVE UNIVERSITY · PI CHANCE, MARK R · NCI · award ends Mar 31, 2030 · Proteomics

    NIH RePORTER · NIH RePORTER 11373660 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources